(Q33368341)

26 July 2017

1 reference

title

Chronic myelomonocytic leukemia: lost in classification? (English)

1 reference

chronic myelomonocytic leukemia

26 July 2017

1 reference

1 reference

David T Bowen

1

1 reference

26 July 2017

publication date

1 March 2005

1 reference

26 July 2017

published in

Hematological Oncology

1 reference

26 July 2017

volume

23

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

26-33

1 reference

Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases

26 July 2017

cites work

1 reference

7 January 2021

Chronic myelomonocytic leukemia--clinicobiological characteristics: a multivariate analysis in a series of 70 cases

1 reference

7 January 2021

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

1 reference

7 January 2021

Problems in the classification of CMML--dysplastic versus proliferative type.

1 reference

7 January 2021

Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution

1 reference

7 January 2021

Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries

1 reference

7 January 2021

Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome

1 reference

7 January 2021

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported i

1 reference

7 January 2021

Myelomonocytic leukemia: disorderly proliferation of all marrow cells

1 reference

7 January 2021

Chronic myelomonocytic leukaemia

1 reference

7 January 2021

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

7 January 2021

Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?

1 reference

7 January 2021

Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells

1 reference

7 January 2021

Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo

1 reference

7 January 2021

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

1 reference

7 January 2021

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

1 reference

7 January 2021

Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score

1 reference

7 January 2021

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

1 reference

7 January 2021

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

1 reference

7 January 2021

Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Français de Cytogénétique Hématologique

1 reference

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

7 January 2021

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

7 January 2021

N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders.

1 reference

7 January 2021

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes

1 reference

7 January 2021

Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.

1 reference

7 January 2021

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

1 reference

7 January 2021

Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

1 reference

7 January 2021

RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)

1 reference

7 January 2021

Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia

1 reference

7 January 2021

Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

7 January 2021

Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors

1 reference

7 January 2021

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

1 reference

7 January 2021

Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia

1 reference

7 January 2021

Proapoptotic BID is required for myeloid homeostasis and tumor suppression

1 reference

7 January 2021

Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes

1 reference

7 January 2021

Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome

1 reference

7 January 2021

Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

7 January 2021

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

7 January 2021

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1 reference

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

7 January 2021

Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival

1 reference

7 January 2021

New prognostic parameters for chronic myelomonocytic leukemia

1 reference

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

7 January 2021

Modern management of myelofibrosis

1 reference

7 January 2021

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

7 January 2021

Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients

1 reference

7 January 2021

Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.745

1 reference

26 July 2017

1 reference